Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Shionogi & Co., Ltd.
  6. News
  7. Summary
    4507   JP3347200002

SHIONOGI & CO., LTD.

(4507)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shionogi : Notice Regarding the Signing of a Memorandum of Understanding with Vietnam for Infectious Disease Control, including COVID-19

11/24/2021 | 06:50pm EST

Press Release

Notice Regarding the Signing of a Memorandum of Understanding with

Vietnam for Infectious Disease Control, including COVID-19

OSAKA, Japan, 25, November, 2021 - Shionogi & Co., Ltd. (hereafter "Shionogi") announced Shionogi has concluded a memorandum of understanding (hereafter "MoU") with the

ADMINISTRATION OF SCIENCE, TECHNOLOGY AND TRAINING - THE MINISTRY OF HEALTH OF THE SOCIALIST REPUBLIC OF VIETNAM (hereinafter "ASTT") for infectious disease control, including COVID-19.

In accordance with this MoU, the ASTT, the Advanced International Joint Stock Company (hereafter "AIC") and Shionogi will continue to discuss cooperation for infectious disease control, including control of COVID-19. Regarding COVID-19, which remains a global crisis, the collaboration will include clinical trials of Shionogi's recombinant protein-basedCOVID-19 vaccine (S-268019) and its oral therapeutic agent (S-217622) in Vietnam, as well as technology transfer for the manufacture of S- 268019 in Vietnam. The MoU will provide the basis formore specific discussions between the three parties.

Shionogi is committed to "Protect people worldwide from the threat of infectious diseases" as our key focus. As COVID-19 continues to have a major impact on people's lives and to represent a worldwide threat, Shionogi recognizes Japan's global role in addressing this pandemic by contributing to effective countermeasures, which is fully aligned with our own mission as a company dedicated to the control of infectious diseases. Therefore, we will work with the Vietnam government and local partners to control infectious diseases, including COVID-19.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-relatedforward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html

Disclaimer

Shionogi & Co. Ltd. published this content on 25 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 November 2021 23:49:05 UTC.


© Publicnow 2021
All news about SHIONOGI & CO., LTD.
01/26Nikkei 225 Off 0.4% on Pandemic, Fed Outlooks
MT
01/21Shionogi & Co., Ltd. - Notice Regarding the Progress of S-217622 to Fight COVID-19
AQ
01/21Shionogi Starts to Submit Clinical Trial Results of Oral COVID-19 Drug
MT
01/20SHIONOGI : Notice Regarding the Progress of S-217622 to Fight COVID-19
PU
01/20Shionogi & Co., Ltd. Announces Notice Regarding the Progress of S-217622 to Fight COVID..
CI
01/18Shionogi & Co-Notice Regarding the Initiation of an Active Control Neutralizing Antibod..
AQ
01/18Shionogi Begins Comparative Phase III Trial of COVID-19 Drug
MT
01/17SHIONOGI : Notice Regarding the Initiation of an Active Control Neutralizing Antibody Comp..
PU
01/17Shionogi & Co., Ltd. Announces Notice Regarding the Initiation of Active Control Neutra..
CI
01/13Pfizer says it applied for Japan gov't approval for oral COVID-19 drug
RE
More news
Analyst Recommendations on SHIONOGI & CO., LTD.
More recommendations
Financials
Sales 2022 308 B 2 672 M 2 672 M
Net income 2022 110 B 958 M 958 M
Net cash 2022 374 B 3 247 M 3 247 M
P/E ratio 2022 17,2x
Yield 2022 1,76%
Capitalization 1 904 B 16 531 M 16 520 M
EV / Sales 2022 4,97x
EV / Sales 2023 4,00x
Nbr of Employees 5 485
Free-Float -
Chart SHIONOGI & CO., LTD.
Duration : Period :
Shionogi & Co., Ltd. Technical Analysis Chart | 4507 | JP3347200002 | MarketScreener
Technical analysis trends SHIONOGI & CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 6 315,00 JPY
Average target price 8 337,69 JPY
Spread / Average Target 32,0%
EPS Revisions
Managers and Directors
Isao Teshirogi Manager-Secretary & Manager-Corporate Planning
Motozo Shiono Director
Teppei Mogi Independent Outside Director
Keiichi Ando Independent Outside Director
Hiroshi Ozaki Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
SHIONOGI & CO., LTD.-22.28%16 531
JOHNSON & JOHNSON0.42%452 254
ROCHE HOLDING AG-6.24%308 691
PFIZER, INC.-7.99%304 947
ABBVIE INC.1.86%243 826
ELI LILLY AND COMPANY-11.27%222 206